It’s one of the most common questions patients ask before starting hormone therapy — and the answer is more nuanced than a simple yes or no. The short version: some bioidentical hormone therapies are FDA-approved, and some are not. Which category your treatment falls into depends on whether you’re using a commercially manufactured product that has gone through the FDA approval process, or a customized formulation prepared by a compounding pharmacy. Understanding the difference matters — not because one is automatically safer than the other, but because it shapes how you evaluate your options, what questions to ask your provider, and what protections and trade-offs apply to your care. The confusion around this topic is partly understandable. "Bioidentical" has become a broad marketing term that gets applied to FDA-approved products, compounded formulations, and everything in between. Patients are told BHRT is "natural" or "the same as what your body makes" without being given a clear picture of what that means from a regulatory standpoint. Some of what you’ve heard may be accurate. Some of it is marketing. This article will walk you through what FDA approval actually means, which bioidentical products carry it, what compounded BHRT is and why it doesn’t carry that label, and how to make a safe, informed decision about your treatment.
What You Need to Know
Bioidentical hormones are hormones that are chemically identical in molecular structure to the hormones your body naturally produces. The most commonly used bioidentical hormones in clinical practice are estradiol (the primary form of estrogen), micronized progesterone, testosterone, and DHEA. The bioidentical designation refers to the hormone’s molecular structure — not to how it was manufactured, who made it, or whether it has been reviewed by the FDA. FDA approval, by contrast, refers to the regulatory review process a drug product undergoes before it can be commercially marketed in the United States. An FDA-approved drug has been evaluated for safety, efficacy, purity, potency, and consistency of manufacturing. The approval is specific to a particular product — a defined dose, formulation, and delivery method manufactured by a specific company under standardized conditions. Here is the key point: bioidentical hormones and FDA approval are not mutually exclusive. There are FDA-approved bioidentical hormone products. There are also bioidentical hormone preparations that are compounded to a patient’s individual specifications and are therefore not FDA-approved as finished drug products. Both categories exist, and understanding the distinction is essential for making an informed decision.
What FDA Approval Actually Means
When a pharmaceutical company seeks FDA approval for a drug, it submits a New Drug Application (NDA) that includes clinical trial data demonstrating the drug’s safety and effectiveness for a specific indication, manufacturing standards ensuring consistent potency and purity, proposed labeling that accurately reflects risks and benefits, and post-marketing surveillance commitments. The FDA reviews this data and, if satisfied, grants approval for that specific product. What FDA approval does not mean is that the drug is risk-free, that it is the only acceptable option for treatment, or that unapproved alternatives are inherently dangerous. The FDA approval process is a regulatory framework for commercially manufactured drug products — it is not the only mechanism through which safe, effective medical care can be delivered. Compounded medications — which are prepared by licensed pharmacies for specific patients based on a provider’s prescription — are regulated differently. They are not FDA-approved as finished drug products because they are not manufactured at scale and submitted for pre-market review. However, compounding pharmacies are regulated by state boards of pharmacy, and those that comply with Current Good Manufacturing Practice (cGMP) standards — called 503B outsourcing facilities — are also subject to FDA oversight. This is a meaningful distinction that often gets lost in oversimplified discussions of the topic.
Which BHRT Products Are FDA-Approved?
Several bioidentical hormone formulations have gone through the FDA approval process and are commercially available as approved drug products. These include:
- Estradiol patches (Vivelle-Dot, Climara, Minivelle, and others): Transdermal delivery that bypasses the liver, available in multiple doses, and well-studied for symptom relief and cardiovascular safety.
- Estradiol gels and sprays (EstroGel, Divigel, Evamist): Applied topically for transdermal absorption. FDA-approved at specific doses.
- Micronized progesterone (Prometrium): The bioidentical form of progesterone in an FDA-approved oral capsule. This is structurally different from synthetic progestins like medroxyprogesterone acetate (MPA) and has a more favorable safety profile in several studies.
- Vaginal estradiol (Vagifem, Estrace Vaginal Cream, Imvexxy, Estring): FDA-approved local estrogen for genitourinary symptoms including vaginal dryness, painful intercourse, and recurrent urinary tract infections.
- Testosterone gels and injections (AndroGel, Testim, Depo-Testosterone, and others): FDA-approved for testosterone deficiency in men. Currently, there are no FDA-approved testosterone products for women, though off-label use is well-supported in the clinical literature and widely practiced.
For most patients, one or more of these FDA-approved options will meet their clinical needs. When they do, these products are generally considered first-line choices because of the established data behind them.
What Is Compounded BHRT — and Why Isn’t It FDA-Approved?
Compounded BHRT is hormone therapy that is custom-prepared by a licensed compounding pharmacy based on a prescriber’s individualized order. The pharmacy combines pharmaceutical-grade hormone ingredients in a specific dose, combination, or delivery method that is not available in any commercially approved product. Common examples include custom-dosed testosterone creams for women, compounded progesterone creams, combination estradiol/testosterone preparations, and pellet implants. Compounded preparations are not FDA-approved as finished drug products because they are not submitted for pre-market review. Each preparation is made individually for a specific patient rather than manufactured at commercial scale. The FDA does not evaluate compounded preparations for safety, efficacy, or consistency before they are dispensed. This does not mean compounded hormones are made from unapproved or low-quality ingredients — the active pharmaceutical ingredients themselves are typically the same bioidentical hormones used in FDA-approved products. The absence of approval applies to the finished product and its specific formulation, not to the underlying hormones. The quality of compounded preparations varies considerably depending on the pharmacy. Traditional 503A compounding pharmacies, which prepare prescriptions for individual patients, are regulated by state boards of pharmacy. 503B outsourcing facilities operate under stricter FDA oversight, follow cGMP standards, and undergo more rigorous quality testing. When compounded BHRT is clinically appropriate, the quality of the compounding pharmacy matters significantly — and a knowledgeable provider will be able to guide you toward pharmacies with verified quality standards.
“Not FDA-Approved” Does Not Mean Unsafe
This distinction deserves emphasis because it is frequently misrepresented in both directions. Some providers dismiss compounded BHRT entirely because it lacks FDA approval, as though the absence of a regulatory stamp makes it inherently dangerous. Others promote compounded preparations as superior to FDA-approved options without adequate evidence to support that claim. Neither position is accurate. The FDA approval process is designed to evaluate commercially manufactured drugs before they reach the market. Compounding has a long, legitimate history in medicine and continues to play an important clinical role in situations where a patient’s needs cannot be met by commercially available products. Physicians routinely prescribe compounded medications for patients who need a dose that isn’t commercially available, who have allergies to inactive ingredients in approved products, or who require a delivery method that doesn’t exist in an approved formulation. That said, the concerns about compounded BHRT are not without basis. Without mandatory pre-market testing, there is greater potential for variability in potency and purity compared to FDA-approved products. Some compounded preparations — particularly pellets — are difficult to reverse or adjust once administered. And the marketing claims made around some compounded BHRT products have outpaced the available evidence. This is exactly why the quality of the prescribing provider and the compounding pharmacy matters, and why treatment decisions should be based on clinical evidence rather than marketing.
When Compounded BHRT Has a Legitimate Role
There are specific clinical situations where compounding fills a genuine gap that FDA-approved products cannot address:
- Testosterone for women: No FDA-approved testosterone product exists for women in the United States. For women who need testosterone therapy for libido, energy, body composition, or bone health, compounded low-dose testosterone is the standard clinical approach — supported by a growing body of evidence.
- Dose customization: FDA-approved products come in fixed doses. Some patients — particularly those who are very sensitive to hormones or who need very low starting doses — require a dose that isn’t commercially available.
- Allergen avoidance: Commercial products contain inactive ingredients — fillers, preservatives, dyes — that some patients cannot tolerate. Compounding allows those ingredients to be excluded.
- Combination preparations: Some patients benefit from a combination of hormones in a single preparation — for example, a cream combining estradiol and testosterone — that is not available as an approved product.
- Delivery method preferences: Patients who cannot use patches, prefer a different cream base, or require a sublingual preparation may be better served by a compounded option.
In these situations, compounding is not a workaround or a fringe approach — it is a clinically appropriate response to a patient’s specific needs. The important principle is that compounding should be used when it serves a genuine clinical purpose, not as a default simply because it can be marketed as more customized or natural.
Safety: What This Means for Your Care
Whether you are using an FDA-approved formulation or a compounded preparation, safe hormone therapy requires the same foundational elements:
- Comprehensive lab testing before initiating any therapy, including a full hormonal panel, metabolic markers, thyroid function, and relevant safety labs.
- Individualized dosing based on your specific lab results, symptoms, health history, and risk factors. Cookie-cutter protocols are not appropriate for hormone therapy, regardless of the formulation used.
- Thorough personal and family history review, including history of hormone-sensitive cancers, blood clots, cardiovascular disease, and liver disease.
- Ongoing monitoring with regular follow-up labs and symptom assessments. Hormone therapy is not a one-time prescription — it requires active, ongoing management.
- Pharmacy quality, if compounded therapy is used. A knowledgeable provider should be able to direct you to pharmacies with verified quality standards and appropriate oversight.
Hormone therapy may not be appropriate for individuals with a history of estrogen-sensitive cancers, blood clots, stroke, active cardiovascular disease, active liver disease, unexplained vaginal bleeding, uncontrolled hypertension, or prostate cancer. Any treatment decision requires a thorough individual risk-benefit analysis with a qualified provider.
Sources
Frequently Asked Questions
Is BHRT FDA-approved?
Some forms of BHRT are FDA-approved, and some are not. FDA-approved bioidentical hormone products include transdermal estradiol patches, gels, and sprays; oral micronized progesterone (Prometrium); vaginal estradiol preparations; and testosterone gels and injections for men. These products have undergone pre-market review for safety, efficacy, and manufacturing consistency. Compounded BHRT — custom-prepared hormone formulations made by a compounding pharmacy to an individual patient’s specifications — is not FDA-approved as a finished drug product, because it is not manufactured at scale or submitted for pre-market review. Both categories involve bioidentical hormones. The FDA approval status reflects the regulatory pathway the product went through, not the nature of the hormone itself.
What bioidentical hormone products are FDA-approved?
Several bioidentical hormone formulations carry full FDA approval. For women, these include estradiol patches (Vivelle-Dot, Climara, Minivelle), estradiol gels and sprays (EstroGel, Divigel, Evamist), oral micronized progesterone (Prometrium), and multiple vaginal estradiol products (Vagifem, Imvexxy, Estring, Estrace Vaginal Cream). For men, FDA-approved testosterone products include injectable testosterone cypionate and enanthate, testosterone gels (AndroGel, Testim, Fortesta), and testosterone patches. For women requiring testosterone therapy, no FDA-approved product currently exists in the United States, which is why low-dose compounded testosterone is the standard clinical approach for that indication.
What is compounded BHRT and why isn’t it FDA-approved?
Compounded BHRT is hormone therapy prepared by a licensed compounding pharmacy based on a provider’s individualized prescription. Rather than using a commercially manufactured product at a fixed dose, the pharmacy creates a preparation with a specific dose, combination of hormones, and delivery method tailored to the patient. Because compounded preparations are made individually rather than manufactured at commercial scale, they are not submitted for FDA pre-market review and are therefore not FDA-approved as finished drug products. This does not mean the underlying hormones are unapproved — the active ingredients are typically pharmaceutical-grade bioidentical hormones. The absence of approval reflects the regulatory pathway for custom-compounded preparations, not a judgment about the safety or legitimacy of compounding as a practice.
Is compounded BHRT safe?
The safety of compounded BHRT depends significantly on the quality of the compounding pharmacy and the clinical oversight of the prescribing provider. Compounding pharmacies that operate as 503B outsourcing facilities are subject to FDA inspection and follow Current Good Manufacturing Practice (cGMP) standards, providing a level of quality assurance that approaches that of commercial manufacturers. Traditional 503A pharmacies are regulated by state boards of pharmacy and vary more widely in quality. When compounded BHRT is prescribed through a knowledgeable provider who directs patients to pharmacies with verified quality standards, appropriate monitoring, and evidence-based dosing, the safety profile is generally comparable to FDA-approved options. The greater concern arises when compounded preparations are used without adequate clinical oversight, at supraphysiologic doses, or without ongoing monitoring.
What does the FDA say about bioidentical hormones?
The FDA’s position is that the term "bioidentical" has no medical or scientific definition that distinguishes these hormones from other forms of hormone therapy in terms of safety or effectiveness. The FDA supports the use of FDA-approved bioidentical hormone products and has raised concerns specifically about unsupported marketing claims made for some compounded BHRT preparations — particularly claims that compounded preparations are safer than FDA-approved products, or that they can be customized based on saliva testing. The FDA does not object to compounding as a practice when it serves a legitimate clinical purpose and is performed within the legal and regulatory framework. The agency’s concerns center on misleading marketing, unverified claims, and the use of unapproved hormone combinations without adequate evidence.
What is the difference between bioidentical hormones and synthetic hormones?
Bioidentical hormones are molecularly identical to the hormones your body naturally produces. Synthetic hormones are structurally similar in function but differ in molecular structure. The most clinically significant example of this distinction is the difference between micronized progesterone (bioidentical) and medroxyprogesterone acetate, or MPA (synthetic progestin). The Women’s Health Initiative study used MPA and found an increased risk of breast cancer with combined hormone therapy. Subsequent studies using micronized progesterone have generally shown a more favorable risk profile. This difference in risk profile is one of the primary reasons many practitioners and professional societies now prefer micronized progesterone over synthetic progestins when progestogenic therapy is needed. The structural difference matters clinically — it is not merely a marketing distinction.
Are hormone pellets FDA-approved?
No. Hormone pellets — small implants inserted under the skin that release hormones gradually over several months — are a compounded preparation and are not FDA-approved. There are no FDA-approved hormone pellets for either men or women. This does not mean pellets are inappropriate for everyone, but it does mean they lack the pre-market safety and efficacy review that approved products have undergone. There are additional clinical considerations specific to pellets: once inserted, they cannot be adjusted or removed if you experience side effects or if your hormone levels become too high. Pellets may be appropriate in specific situations, but they are generally not considered first-line therapy and should be approached with careful informed consent and ongoing monitoring.
Does “natural” or “bioidentical” mean safer than other hormone therapy?
Not automatically, and this is one of the most important misconceptions to address. "Bioidentical" refers to molecular structure, not to a safety guarantee. Bioidentical hormones still carry real physiological effects and real risks in the wrong patient, at the wrong dose, or without appropriate monitoring. The clinical evidence does support some meaningful distinctions — particularly between micronized progesterone and synthetic progestins — but those distinctions are supported by specific comparative studies, not by the general principle that "natural is safer." What makes hormone therapy safer is proper patient selection, appropriate dosing guided by lab work, choosing the right delivery method for the individual patient’s risk profile, and ongoing monitoring. Those principles apply equally to FDA-approved and compounded BHRT.
Why do some providers use compounded BHRT when FDA-approved options are available?
There are legitimate clinical reasons to use compounded preparations even when FDA-approved options exist. FDA-approved products come in fixed doses, fixed formulations, and fixed delivery methods. Some patients need a dose that isn’t commercially available — for example, a very low starting dose of estradiol for a hormone-sensitive patient, or a microdose of testosterone for a woman. Some patients have allergies or sensitivities to inactive ingredients in commercial products. Some need a hormone combination that no approved product provides. In these situations, compounding fills a real gap. The concern arises when compounding is used as a default rather than as a targeted solution to a specific clinical need, or when marketing claims about superiority drive the decision rather than patient-specific clinical factors.
Can I get FDA-approved BHRT through a regular pharmacy?
Yes. FDA-approved bioidentical hormone products — including estradiol patches, gels, and sprays; oral micronized progesterone (Prometrium); and testosterone gels and injections for men — are commercially available and can be filled at standard retail or mail-order pharmacies with a valid prescription. Insurance coverage for these products varies depending on your plan and the specific indication. Some patients find that FDA-approved products are not only clinically appropriate but also more accessible and cost-effective than compounded preparations, particularly when insurance coverage applies. Your provider can help you navigate coverage options and determine which formulation and delivery method best fits your clinical needs and practical circumstances.
What should I look for in a BHRT provider?
The most important qualities in a BHRT provider are a commitment to comprehensive testing before initiating therapy, individualized dosing based on your lab results and symptoms rather than a standard protocol, transparent discussion of both FDA-approved and compounded options and the evidence behind each, thorough review of your personal and family health history, and ongoing monitoring after therapy begins. A good provider should be able to explain why they are recommending a particular formulation, what monitoring schedule they follow, and what signs would prompt them to adjust or discontinue therapy. Be cautious of providers who rely on saliva testing alone to dose hormones (blood and/or urine testing is more reliable and widely validated), who promote a single approach for all patients, or who make marketing claims that any therapy is completely risk-free.
Do you offer telehealth appointments?
Yes. We offer telehealth consultations for patients who prefer virtual visits or live outside our local area. Lab kits can be mailed directly to you, and consultations, lab reviews, protocol design, and ongoing monitoring can all be managed via video appointments. We serve clients nationwide.
This content is for educational purposes and does not substitute personalized medical advice.
